Edward Jordan
Corporate Officer/Principal presso XSPRAY PHARMA AB
Patrimonio netto: - $ in data 31/05/2024
Profilo
Edward P.
Jordan is currently the Chief Commercial Officer at Xspray Pharma AB since 2023.
Prior to this, he was the Chief Commercial Officer at Humanigen, Inc. from 2020 to 2023 and Senior Vice President at DBV Technologies, Inc. from 2016 to 2020.
He also held a senior leadership position at AMAG Pharmaceuticals, Inc. Mr. Jordan has an undergraduate degree from the University of Rhode Island and an MBA from Southern New Hampshire University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
HUMANIGEN INC
0.01% | 11/04/2023 | 12 500 ( 0.01% ) | - $ | 31/05/2024 |
Posizioni attive di Edward Jordan
| Società | Posizione | Inizio |
|---|---|---|
| XSPRAY PHARMA AB | Corporate Officer/Principal | 15/09/2023 |
Precedenti posizioni note di Edward Jordan
| Società | Posizione | Fine |
|---|---|---|
| HUMANIGEN, INC. | Corporate Officer/Principal | 14/09/2023 |
DBV Technologies, Inc.
 DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The company is based in New York, NY. | Corporate Officer/Principal | 24/08/2020 |
| AMAG PHARMACEUTICALS, INC. | Vendite & Marketing | - |
Formazione di Edward Jordan
| University of Rhode Island | Undergraduate Degree |
| Southern New Hampshire University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| Aziende private | 2 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
DBV Technologies, Inc.
DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The company is based in New York, NY. | Health Services |
- Borsa valori
- Insiders
- Edward Jordan
